» Articles » PMID: 19784733

Chemotherapy-induced Sclerosing Cholangitis As a Rare Indication for Resection: Report of a Case

Overview
Journal Surg Today
Specialty General Surgery
Date 2009 Sep 29
PMID 19784733
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Bile duct stricture due to chemotherapy-induced sclerosing cholangitis (CISC) is a potentially fatal complication of hepatic arterial infusion chemotherapy (HAIC). It is managed primarily with medical treatment and biliary stenting. We report a rare case of a CISC-related biliary stricture requiring resection. The patient had been receiving adjuvant HAIC for 11 months after a curative liver resection for hepatocellular carcinoma, when clinically overt cholangitis developed. Radiologic and biopsy findings suggested a CISC-related biliary stricture limited to the common hepatic duct. We discontinued HAIC and started corticosteroid treatment, which finally became ineffective. Endoscopic biliary stenting was impossible because of her severe biliary sclerosis, necessitating resection of the stricture, which was confirmed histologically to be secondary sclerosing cholangitis. The patient has shown no signs of recurrent cholangitis for 12 postoperative months since her operation. Thus, resection could be a treatment option for a CISC-related biliary stricture in selected patients.

Citing Articles

Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment.

Ueshima K, Komemushi A, Aramaki T, Iwamoto H, Obi S, Sato Y Liver Cancer. 2022; 11(5):407-425.

PMID: 36158592 PMC: 9485983. DOI: 10.1159/000524893.


Secondary Sclerosing Cholangitis due to Gallbladder Adenocarcinoma.

Fan D, Sorser S, Gamarra R Case Rep Gastroenterol. 2013; 7(1):134-9.

PMID: 23626514 PMC: 3617886. DOI: 10.1159/000345961.


The current diagnosis and treatment of benign biliary stricture.

Shimada H, Endo I, Shimada K, Matsuyama R, Kobayashi N, Kubota K Surg Today. 2012; 42(12):1143-53.

PMID: 23001533 DOI: 10.1007/s00595-012-0333-3.

References
1.
Campos L . A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer. 1993; 71(3):875-6. DOI: 10.1002/1097-0142(19930201)71:3<875::aid-cncr2820710337>3.0.co;2-r. View

2.
Hohn D, MELNICK J, Stagg R, Altman D, Friedman M, Ignoffo R . Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol. 1985; 3(1):98-102. DOI: 10.1200/JCO.1985.3.1.98. View

3.
Kouraklis G . A gallbladder conduit for bile duct reconstruction to treat benign biliary stenosis. Surg Today. 2006; 36(8):761-3. DOI: 10.1007/s00595-006-3235-4. View

4.
Fukuzumi S, Moriya Y, Makuuchi M, Terui S . Serious chemical sclerosing cholangitis associated with hepatic arterial 5FU and MMC chemotherapy. Eur J Surg Oncol. 1990; 16(3):251-5. View

5.
Rougier P, Laplanche A, Huguier M, Hay J, Ollivier J, Escat J . Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992; 10(7):1112-8. DOI: 10.1200/JCO.1992.10.7.1112. View